Showing results (11-20 of 143) with videos related to

Sort By:
Pageof 15
Antimicrobial Agents and Chemotherapy|June 19, 2002
ATP-dependent removal of nucleoside reverse transcriptase inhibitors by human immunodeficiency virus type 1 reverse transcriptaseLisa K Naeger, Nicolas A Margot, Michael D Miller
Antimicrobial Agents and Chemotherapy|September 20, 2006
In vitro human immunodeficiency virus type 1 resistance selections with combinations of tenofovir and emtricitabine or abacavir and lamivudineN A Margot, J M Waters, M D Miller
AIDS (London, England)|April 7, 2007
Long-term follow-up of patients taking tenofovir DF with low-level HIV-1 viremia and the K65R substitution in HIV-1 RTBrandi J Chappell, Nicolas A Margot, Michael D Miller
Nucleosides, Nucleotides & Nucleic Acids|September 21, 2001
Tenofovir (PMPA) is less susceptible to pyrophosphorolysis and nucleotide-dependent chain-terminator removal than zidovudine or stavudineL K Naeger, N A Margot, M D Miller
Antimicrobial Agents and Chemotherapy|March 24, 2010
Phenotypic susceptibility to bevirimat in isolates from HIV-1-infected patients without prior exposure to bevirimatNicolas A Margot, Craig S Gibbs, Michael D Miller
Annals of Physical and Rehabilitation Medicine|November 14, 2009
What are the risk factors of occurence and chronicity of neuropathic pain in spinal cord injury patients?A Margot-Duclot, H Tournebise, M Ventura, et al.
Antiviral Therapy|August 9, 2001
Increased drug susceptibility of HIV-1 reverse transcriptase mutants containing M184V and zidovudine-associated mutations: analysis of enzyme processivity, chain-terminator removal and viral replicationL K Naeger, N A Margot, M D Miller
Biochimie|March 1, 1985
Survival and mutagenesis of ultraviolet irradiated simian virus 40 in foetal human fibroblastsA Gentil, L Daya-Grosjean, A Margot, et al.
Antimicrobial Agents and Chemotherapy|July 8, 2015
Characterization of HIV-1 Resistance to Tenofovir Alafenamide In VitroNicolas A Margot, Audun Johnson, Michael D Miller, et al.
HIV Medicine|August 24, 2006
Resistance development over 144 weeks in treatment-naive patients receiving tenofovir disoproxil fumarate or stavudine with lamivudine and efavirenz in Study 903N A Margot, B Lu, A Cheng, et al.
Pageof 15